Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abiomed Inc (ABMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,024,005
  • Shares Outstanding, K 45,086
  • Annual Sales, $ 593,750 K
  • Annual Income, $ 112,170 K
  • 60-Month Beta 0.37
  • Price/Sales 24.73
  • Price/Cash Flow 117.05
  • Price/Book 17.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 1.07
  • Number of Estimates 7
  • High Estimate 1.13
  • Low Estimate 1.03
  • Prior Year 0.80
  • Growth Rate Est. (year over year) +33.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
305.37 +9.13%
on 03/08/19
364.31 -8.53%
on 02/19/19
-28.81 (-7.96%)
since 02/15/19
3-Month
274.02 +21.62%
on 12/24/18
364.31 -8.53%
on 02/19/19
+28.45 (+9.33%)
since 12/18/18
52-Week
274.02 +21.62%
on 12/24/18
459.75 -27.51%
on 10/01/18
+40.20 (+13.72%)
since 03/16/18

Most Recent Stories

More News
Allscripts Partners With Opargo to Boost Practice Management

Allscripts' (MDRX) partnership with Opargo is likely to improve scheduling capabilities and practice workflows of Allscripts Practice Management solution.

WMGI : 32.16 (-0.53%)
ABMD : 333.25 (+0.01%)
MDRX : 10.45 (-1.69%)
IDXX : 215.74 (-0.22%)
Omnicell's Global Expansion on Track, Stiff Competition Ails

Although Omnicell (OMCL) is steadily expanding in the Middle East and South African belts, it sees a greater uptake of technologies across other regions of the world.

OMCL : 83.31 (-1.69%)
VAR : 135.57 (-0.75%)
ABMD : 333.25 (+0.01%)
MASI : 132.26 (-0.93%)
Is ABIOMED (ABMD) Outperforming Other Medical Stocks This Year?

Is (ABMD) Outperforming Other Medical Stocks This Year?

ABMD : 333.25 (+0.01%)
BioScrip (BIOS) Reports Loss in Q4, Both Margins Contract

The combined expertise of BioScrip (BIOS) and OptionCare is expected to drive significant growth for the former.

BIOS : 2.34 (-15.83%)
ABMD : 333.25 (+0.01%)
VAR : 135.57 (-0.75%)
CNMD : 79.81 (+1.15%)
Impella RP Post-Approval Study Data Presented at ACC 2019

Abiomed (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies and the maker of the Impella RP heart pump, announces that survival data from the 18 month ...

ABMD : 333.25 (+0.01%)
Stryker Buys Israel-Based OrthoSpace, Strengthens MedSurg

Strong international presence and an acquisition-driven strategy are likely to fortify Stryker's (SYK) footprint in the global MedTech space.

WMGI : 32.16 (-0.53%)
SYK : 193.58 (-0.24%)
ABMD : 333.25 (+0.01%)
IDXX : 215.74 (-0.22%)
Integra's Duragen Secures Japanese Nod to Drive Global Growth

Despite facing adverse foreign exchange volatility across its international business, Integra LifeSciences (IART) can successfully eye certain key developments on foreign shores.

ABMD : 333.25 (+0.01%)
PEN : 152.21 (-2.01%)
IART : 55.70 (-0.55%)
MASI : 132.26 (-0.93%)
Abbott (ABT) Gets FDA Approval for Expanded Use of MitraClip

The FDA approval is expected to strengthen Abbott's (ABT) structural heart business.

ABT : 78.83 (-1.29%)
ABMD : 333.25 (+0.01%)
VAR : 135.57 (-0.75%)
MASI : 132.26 (-0.93%)
Allscripts Strengthens Strategic Relationship with Pulse8

Pulse8 is likely to boost Allscripts' (MDRX) flagship platform Veradigm, and its existing health plan product suite that delivers pocket-friendly tools and services for health plan members.

WMGI : 32.16 (-0.53%)
ABMD : 333.25 (+0.01%)
MDRX : 10.45 (-1.69%)
IDXX : 215.74 (-0.22%)
Tandem Diabetes (TNDM) Hits a 52-Week High on Solid Prospects

Tandem Diabetes Care's (TNDM) growth in pump shipments drives the top line significantly.

TNDM : 71.31 (-2.52%)
ABMD : 333.25 (+0.01%)
PEN : 152.21 (-2.01%)
MASI : 132.26 (-0.93%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Steady.

See More Share

Trade ABMD with:

Business Summary

Abiomed, Inc. is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing...

See More

Key Turning Points

2nd Resistance Point 339.97
1st Resistance Point 336.61
Last Price 333.25
1st Support Level 329.28
2nd Support Level 325.31

See More

52-Week High 459.75
Fibonacci 61.8% 388.80
Fibonacci 50% 366.89
Fibonacci 38.2% 344.97
Last Price 333.25
52-Week Low 274.02

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar